Business Context and Reporting Period
This Form 8-K, dated January 23, 2026, reports the completion of the U.S. Domestication of Indivior PLC (Indivior U.K.) into Indivior Pharmaceuticals, Inc. (Indivior U.S.), a Delaware corporation. Effective at the close of market trading on January 23, 2026, Indivior U.K. became a wholly-owned subsidiary of Indivior U.S. pursuant to a court-approved Scheme of Arrangement. Indivior U.K. ordinary shares were cancelled and exchanged on a one-for-one basis for Indivior U.S. common stock. Trading of Indivior U.S. common stock under the symbol "INDV" commenced on January 26, 2026, on the Nasdaq Global Select Market.
Key Financial Metrics
This filing is a current report regarding corporate restructuring and governance changes; it does not contain audited financial statements, revenue, profit, cash flow, or margin data for a specific reporting period. The filing notes that following the domestication, financial statements and results of operations will be reported by Indivior U.S. rather than Indivior U.K.
Key financial-related items disclosed include:
- Debt Obligations: A First Amendment to the Note Purchase Agreement (dated November 4, 2024) became effective January 26, 2026, to reflect the change in reporting entity from Indivior U.K. to Indivior U.S.
- Equity Capitalization: Indivior U.S. authorized capital stock consists of 700,000,000 shares of common stock ($0.001 par value) and 70,000,000 shares of preferred stock ($0.01 par value).
- Director Compensation: Non-employee directors receive annual cash retainers ranging from $75,000 to $100,000 plus equity awards (Restricted Stock Units) with grant date fair values of $250,000 (members) or $400,000 (Chairperson) annually.
Material Changes Versus Prior Period
The primary material change is the shift in corporate domicile from England and Wales to Delaware, United States. Key changes include:
- Corporate Structure: Indivior U.K. is now a subsidiary of Indivior U.S., which is the ultimate parent company.
- Securities Listing: Indivior U.K. ordinary shares were delisted; Indivior U.S. common stock is now the registered security trading under the symbol "INDV" with CUSIP 45579U109.
- Governance: The board of directors and executive officers of Indivior U.K. automatically became the directors and officers of Indivior U.S. New indemnification agreements were executed with all directors and executive officers.
- Equity Plans: Existing equity incentive plans were assumed and amended to issue Indivior U.S. common stock. A new "2026 Omnibus Equity Incentive Plan" was adopted with a share reserve of 17,500,000 shares.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing confirms the successful completion of the domestication strategy. No specific financial guidance or operational outlook is provided in this document.
Risks and Contingencies:
- Anti-Takeover Provisions: The new Delaware Certificate of Incorporation and Bylaws include provisions that may discourage or delay changes in control, including Section 203 of the Delaware General Corporation Law, undesignated preferred stock authority, and restrictions on stockholder actions by written consent.
- Legal Forum: The Certificate designates the Court of Chancery of the State of Delaware as the exclusive forum for most corporate claims and federal district courts for Securities Act claims.
- Liability Limitations: The Certificate limits the personal liability of directors and officers for monetary damages for breaches of fiduciary duty, subject to Delaware law exceptions.
Important Facts for Investor Verification
- Verify the trading status of the new ticker symbol "INDV" on Nasdaq starting January 26, 2026.
- Review the First Amendment to the Note Purchase Agreement (Exhibit 99.1) to understand any specific covenants or terms modified for the U.S. entity.
- Confirm the terms of the new 2026 Omnibus Equity Incentive Plan (Exhibit 10.6) regarding the 17.5 million share reserve and vesting schedules.
- Examine the Non-Employee Director Compensation Policy (Exhibit 10.7) for details on cash retainers and equity grant values.
- Check the Certificate of Incorporation (Exhibit 3.1) for specific anti-takeover provisions and the authorized share count.